VEGA-1 Phase 2 Clinical Trial To Evaluate The Efficacy Of Phentolamine Ophthalmic Solution And Low-Dose Pilocarpine For The Treatment Of Presbyopia
Phentolamine Ophthalmic Solution 0.75%
Presented at American Academy of Ophthalmology 2021
Filter by:
VEGA-1 Phase 2 Clinical Trial To Evaluate The Efficacy Of Phentolamine Ophthalmic Solution And Low-Dose Pilocarpine For The Treatment Of Presbyopia
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2021
MIRA-2 Phase 3 Clinical Trial to Evaluate the Efficacy of Phentolamine Ophthalmic Solution on the Reversal of Pharmacologically Induced Mydriasis
Phentolamine Ophthalmic Solution 0.75%
Presented at American Society of Cataract and Refractive Surgery 2021
Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling
APX3330
Indiana University School of Medicine
Bridging population pharmacokinetic and physiologically based pharmacokinetic approaches to evaluate APX3330 disposition
APX3330
Indiana University School of Medicine
Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial
Phentolamine Ophthalmic Solution 0.75%
Optometry and Vision Science
Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial
Phentolamine Ophthalmic Solution 0.75%
Clinical Ophthalmology 2021
Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
APX3330
Inflammatory Bowel Disease 2020
The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease
APX3330
Drug Discovery Today 2020
